SMTL ID : 6ak4.1

Crystal structure of human FTO in complex with small-molecule inhibitors

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 2.80 Å

Oligo State

monomer

Ligands

1 x ZN: ZINC ION(Non-covalent)

ZN.1: 4 residues within 4Å: Chain A: H.196, D.198, H.272 Ligands: PD9.2 3 PLIP interactions: 3 interactions with chain A Metal complexes: A:H.196, A:D.198, A:H.272

1 x PD9: (~{E})-2-cyano-~{N},~{N}-diethyl-3-[3-nitro-4,5-bis(oxidanyl)phenyl]prop-2-enamide(Non-covalent)

PD9.2: 17 residues within 4Å: Chain A: R.86, Y.96, Y.98, L.99, N.170, V.193, H.196, D.198, V.209, Y.260, H.272, V.274, R.281, S.283, T.285, R.287 Ligands: ZN.1 6 PLIP interactions: 6 interactions with chain A Hydrophobic interactions: A:V.193, A:V.209, A:V.274, A:T.285 Hydrogen bonds: A:R.287, A:R.287

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Peng, S. et al., Identification of entacapone as a chemical inhibitor of FTO mediating metabolic regulation through FOXO1. Sci Transl Med (2019)

Release Date

2019-07-10

Peptides

Alpha-ketoglutarate-dependent dioxygenase FTO,Alpha-ketoglutarate-dependent dioxygenase FTO: A

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

Alpha-ketoglutarate-dependent dioxygenase FTO,Alpha-ketoglutarate-dependent dioxygenase FTO

Related Entries With Identical Sequence